The Oncology Institute Announces Certification to Administer Pluvicto Therapy in California

$TOI
Medical/Nursing Services
Health Care
Get the next $TOI alert in real time by email

CERRITOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) announced that they have received certification to begin administering Pluvicto therapy in their outpatient California radiation oncology practices. Pluvicto, a radiopharmaceutical used to treat certain types of metastatic prostate cancer, has previously been administered primarily in hospital settings.

"We are ecstatic about the opportunity to offer this new therapeutic alternative to our patients," said Dr. Geoffrey Geiger, Medical Director of Radiation Oncology at TOI. "This aligns perfectly with TOI's mission to deliver state-of-the-art therapy in the community and provide value for our patients and payor partners."

Jeremy Castle, Chief Operations Officer, added, "The launch of our radiopharmaceutical program marks a significant step forward in our radiation oncology growth strategy. By providing this treatment in the outpatient setting, we can reduce the need for costly hospitalizations, benefiting patients, payors, and our organization alike. It's a win for all involved"

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Investors

Solebury Strategic Communications

investors@theoncologyinstitute.com



Primary Logo

Get the next $TOI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TOI

DatePrice TargetRatingAnalyst
2/26/2024$2.50Buy
Jefferies
9/14/2022$7.00Buy
Guggenheim
8/15/2022$10.00Buy
Jefferies
More analyst ratings

$TOI
Press Releases

Fastest customizable press release news feed in the world

See more
  • TOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1

    CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents. The Florida Oncology Network includes TOI Clinics and a robust panel of value-focused medical and radiation oncologists strategically located throughout the state. The network is designed to provide comprehensive cancer care that is accessible, affordable, and focused on outcomes for patients and payor partners.

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025

    CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Announces $16.5 million Private Placement

    CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities purchase agreement (the "Securities Purchase Agreement") with accredited investors for a private placement that is expected to result in gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses (the "Private Placement"). The Private Placement includes participation from existing investors, as well as members of the Company's management team and Board of Directors and is expected to close on March

    $TOI
    Medical/Nursing Services
    Health Care

$TOI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TOI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TOI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TOI
SEC Filings

See more

$TOI
Leadership Updates

Live Leadership Updates

See more
  • Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute

    CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Names Jeremy Castle as Chief Operations Officer

    CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Announces Leadership Transition

    CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres

    $TOI
    Medical/Nursing Services
    Health Care

$TOI
Financials

Live finance-specific insights

See more
  • The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025

    CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024. Recent Operational Highlights Cash flow from operations in Q4 2024 was approximately $4.2 million, due to disciplined working capital management that saw improvements across receivables, inventory, and payables.Selling, general, and administrative expenses decreased 12% in Q4 2024 as compared to the prior year period, as a result of our ongoing efforts to streamline operations, improve efficiency, and o

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

    CERRITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, March 25, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the

    $TOI
    Medical/Nursing Services
    Health Care
  • The Oncology Institute Reports Third Quarter 2024 Financial Results

    CERRITOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and nine months ended September 30, 2024. Recent Operational Highlights Include 79.9% increase in Dispensary segment revenue compared to prior year quarterWelcomed Rob Carter, as our new Chief Financial Officer3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings to 13 our 2024 newly signed capitation contractsStarted second capitation contract in Florida directly with a health plan

    $TOI
    Medical/Nursing Services
    Health Care

$TOI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more